D. Western Therapeutics Institute Inc
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract su… Read more
Market Cap & Net Worth: D. Western Therapeutics Institute Inc (6DW)
D. Western Therapeutics Institute Inc (F:6DW) has a market capitalization of $26.60 Million (€25.92 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #24964 globally and #2736 in its home market, demonstrating a 4.24% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying D. Western Therapeutics Institute Inc's stock price €0.49 by its total outstanding shares 52676826 (52.68 Million).
D. Western Therapeutics Institute Inc Market Cap History: 2015 to 2026
D. Western Therapeutics Institute Inc's market capitalization history from 2015 to 2026. Data shows change from $195.58 Million to $26.60 Million (-18.40% CAGR).
D. Western Therapeutics Institute Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how D. Western Therapeutics Institute Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.13x
D. Western Therapeutics Institute Inc's market cap is 0.13 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $195.58 Million | $61.00 Million | -$296.00 Million | 3.21x | N/A |
| 2016 | $146.48 Million | $168.00 Million | -$253.51 Million | 0.87x | N/A |
| 2017 | $189.20 Million | $254.03 Million | -$1.56 Billion | 0.74x | N/A |
| 2018 | $227.64 Million | $292.92 Million | -$748.97 Million | 0.78x | N/A |
| 2019 | $270.36 Million | $580.53 Million | $133.20 Million | 0.47x | 2.03x |
| 2020 | $106.52 Million | $355.59 Million | -$276.10 Million | 0.30x | N/A |
| 2021 | $83.81 Million | $414.42 Million | -$149.00 Million | 0.20x | N/A |
| 2022 | $94.62 Million | $448.10 Million | -$429.69 Million | 0.21x | N/A |
| 2023 | $43.53 Million | $428.36 Million | -$812.41 Million | 0.10x | N/A |
| 2024 | $60.56 Million | $471.58 Million | -$1.29 Billion | 0.13x | N/A |
Competitor Companies of 6DW by Market Capitalization
Companies near D. Western Therapeutics Institute Inc in the global market cap rankings as of March 18, 2026.
Key companies related to D. Western Therapeutics Institute Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
D. Western Therapeutics Institute Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, D. Western Therapeutics Institute Inc's market cap moved from $195.58 Million to $ 26.60 Million, with a yearly change of -18.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €26.60 Million | +4.68% |
| 2025 | €25.41 Million | -58.04% |
| 2024 | €60.56 Million | +39.13% |
| 2023 | €43.53 Million | -54.00% |
| 2022 | €94.62 Million | +12.90% |
| 2021 | €83.81 Million | -21.32% |
| 2020 | €106.52 Million | -60.60% |
| 2019 | €270.36 Million | +18.76% |
| 2018 | €227.64 Million | +20.32% |
| 2017 | €189.20 Million | +29.16% |
| 2016 | €146.48 Million | -25.10% |
| 2015 | €195.58 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of D. Western Therapeutics Institute Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $26.60 Million USD |
| MoneyControl | $26.60 Million USD |
| MarketWatch | $26.60 Million USD |
| marketcap.company | $26.60 Million USD |
| Reuters | $26.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.